Reviews
Zheng Su, Dian Xiao, Fei Xie, Lianqi Liu, Yanming Wang, Shiyong Fan, Xinbo Zhou, Song Li. Antibody-drug conjugates: Recent advances in linker chemistry[J]. Acta Pharmaceutica Sinica B, 2021, 11(12): 3889-3907

Antibody-drug conjugates: Recent advances in linker chemistry
Zheng Sua,b, Dian Xiaob, Fei Xieb, Lianqi Liub, Yanming Wangb, Shiyong Fanb, Xinbo Zhoub, Song Lia,b
a. School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China;
b. National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China
Abstract:
Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the efficacy and the adverse effects, and so has a major influence on the fate of ADCs. An ideal linker should be stable in the circulatory system and release the cytotoxic payload specifically in the tumor. However, existing linkers often release payloads nonspecifically and inevitably lead to off-target toxicity. This defect is becoming an increasingly important factor that restricts the development of ADCs. The pursuit of ADCs with optimal therapeutic windows has resulted in remarkable progress in the discovery and development of novel linkers. The present review summarizes the advance of the chemical trigger, linker-antibody attachment and linker-payload attachment over the last 5 years, and describes the ADMET properties of ADCs. This work also helps clarify future developmental directions for the linkers.
Key words:    Antibody–drug conjugate    Linker    Chemical trigger    Linker-antibody attachment    Linker-payload attachment   
Received: 2021-01-18     Revised: 2021-03-17
DOI: 10.1016/j.apsb.2021.03.042
Funds: This work was funded by the Chinese National Natural Science Foundation (Grant Nos. 81872736 and 81903451), and the China Postdoctoral Science Foundation (Grant No. 2019M664015).
Corresponding author: Shiyong Fan,E-mail:fsyn1996@163.com;Xinbo Zhou,E-mail:zhouxinbo@bmi.ac.cn     Email:fsyn1996@163.com;zhouxinbo@bmi.ac.cn
Author description:
Service
PDF(KB) Free
Print
0
Authors
Zheng Su
Dian Xiao
Fei Xie
Lianqi Liu
Yanming Wang
Shiyong Fan
Xinbo Zhou
Song Li

References:
[1] Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008; 8: 473-480
[2] Lamb YN. Inotuzumab ozogamicin: first global approval. Drugs 2017; 77: 1603-1610
[3] Dhillon S. Moxetumomab pasudotox: first global approval. Drugs 2018; 78: 1763-1767
[4] Deeks ED. Correction to: Polatuzumab vedotin: first global approval. Drugs 2019; 79: 1829
[5] Chang E, Weinstock C, Zhang L, Charlab R, Dorff SE, Gong Y, et al. FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma. Clin Cancer Res 2020;27:922-927
[6] Greenblatt K, Khaddour K. Trastuzumab. StatPearls Publishing LLC. Dec 19, 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532246/
[7] Markham A. Belantamab mafodotin: first approval. Drugs 2020; 80: 1607-1613
[8] Wahby S, Fashoyin-Aje L, Osgood CL, Cheng J, Fiero MH, Zhang L, et al. FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third line treatment of metastatic triple-negative breast cancer (mTNBC). Clin Cancer Res 2021;27:1850-4
[9] Lyon R. Drawing lessons from the clinical development of antibody-drug conjugates. Drug Discov Today Technol 2018; 30: 105-109
[10] Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002; 13: 47-58
[11] Perini GF, Pro B. Brentuximab vedotin in CD30+ lymphomas. Biol Ther 2013; 3: 15-23
[12] Lambert JM, Chari RV. Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2- positive breast cancer. J Med Chem 2014; 57: 6949-6964
[13] Othus M, Appelbaum FR, Petersdorf SH, Kopecky KJ, Slovak M, Nevill T, et al. Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 2015; 21: 559-564
[14] Dovgan I, Kolodych S, Koniev O, Wagner A. 2-(Maleimidomethyl)-1,3-dioxanes (MD): a serum-stable self-hydrolysable hydrophilic alternative to classical maleimide conjugation. Sci Rep 2016; 6: 30835
[15] Ponte JF, Sun X, Yoder NC, Fishkin N, Laleau R, Coccia J, et al. Understanding how the stability of the thiol-maleimide linkage impacts the pharmacokinetics of lysine-linked antibody-maytansinoid conjugates. Bioconjug Chem 2016; 27: 1588-1598
[16] Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, et al. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. J Med Chem 2014; 57: 7890-7899
[17] Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature 2015; 527: 323-328
[18] Kern JC, Cancilla M, Dooney D, Kwasnjuk K, Zhang R, Beaumont M, et al. Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody-drug conjugates. J Am Chem Soc 2016; 138: 1430-1445
[19] Caculitan NG, Dela Cruz Chuh J, Ma Y, Zhang D, Kozak KR, Liu Y, et al. Cathepsin B is dispensable for cellular processing of cathepsin B-cleavable antibody-drug conjugates. Cancer Res 2017; 77: 7027-7037
[20] Wei B, Gunzner-Toste J, Yao H, Wang T, Wang J, Xu Z, et al. Discovery of peptidomimetic antibody-drug conjugate linkers with enhanced protease specificity. J Med Chem 2018; 61: 989-1000
[21] Dorywalska M, Dushin R, Moine L, Farias SE, Zhou D, Navaratnam T, et al. Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design. Mol Cancer Ther 2016; 15: 958-970
[22] Singh R, Setiady YY, Ponte J, Kovtun YV, Lai KC, Hong EE, et al. A new triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells. Mol Cancer Ther 2016; 15: 1311-1320
[23] Wang Y, Fan S, Zhong W, Zhou X, Li S. Development and properties of valine-alanine based antibody-drug conjugates with monomethyl auristatin E as the potent payload. Int J Mol Sci 2017; 18: 1860
[24] Reid EE, Archer KE, Shizuka M, Wilhelm A, Yoder NC, Bai C, et al. Effect of linker stereochemistry on the activity of indolinobenzodiazepine containing antibody-drug conjugates (ADCs). ACS Med Chem Lett 2019; 10: 1193-1197
[25] Salomon PL, Reid EE, Archer KE, Harris L, Maloney EK, Wilhelm AJ, et al. Optimizing lysosomal activation of antibody-drug conjugates (ADCs) by incorporation of novel cleavable dipeptide linkers. Mol Pharm 2019; 16: 4817-4825
[26] Casey JR, Grinstein S, Orlowski J. Sensors and regulators of intracellular pH. Nat Rev Mol Cell Biol 2010; 11: 50-61
[27] Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther 2013; 12: 968-978
[28] Wang Y, Fan S, Xiao D, Xie F, Li W, Zhong W, et al. Novel silyl ether-based acid-cleavable antibody-MMAE conjugates with appropriate stability and efficacy. Cancers (Basel) 2019; 11: 957
[29] Mills BJ, Lang CA. Differential distribution of free and bound glutathione and cyst(e)ine in human blood. Biochem Pharmacol 1996; 52: 401-406
[30] Pillow TH, Sadowsky JD, Zhang D, Yu SF, Del Rosario G, Xu K, et al. Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates. Chem Sci 2017; 8: 366-370
[31] Pillow TH, Schutten M, Yu SF, Ohri R, Sadowsky J, Poon KA, et al. Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody-drug conjugates with self-immolative disulfide linkers. Mol Cancer Ther 2017; 16: 871-878
[32] Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer 2013; 13: 342-355
[33] Spangler B, Fontaine SD, Shi Y, Sambucetti L, Mattis AN, Hann B, et al. A novel tumor-activated prodrug strategy targeting ferrous iron is effective in multiple preclinical cancer models. J Med Chem 2016; 59: 11161-11170
[34] Spangler B, Kline T, Hanson J, Li X, Zhou S, Wells JA, et al. Toward a ferrous iron-cleavable linker for antibody-drug conjugates. Mol Pharm 2018; 15: 2054-2059
[35] Jeffrey SC, Andreyka JB, Bernhardt SX, Kissler KM, Kline T, Lenox JS, et al. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. Bioconjug Chem 2006; 17: 831-840
[36] Kolodych S, Michel C, Delacroix S, Koniev O, Ehkirch A, Eberova J, et al. Development and evaluation of beta-galactosidase-sensitive antibody-drug conjugates. Eur J Med Chem 2017; 142: 376-382
[37] Bargh JD, Walsh SJ, Isidro-Llobet A, Omarjee S, Carroll JS, Spring DR. Sulfatase-cleavable linkers for antibody-drug conjugates. Chem Sci 2020; 11: 2375-2380
[38] Kern JC, Dooney D, Zhang R, Liang L, Brandish PE, Cheng M, et al. Novel phosphate modified cathepsin B linkers: improving aqueous solubility and enhancing payload scope of ADCs. Bioconjug Chem 2016; 27: 2081-2088
[39] Carl PL, Chakravarty PK, Katzenellenbogen JA. A novel connector linkage applicable in prodrug design. J Med Chem 1981; 24: 479-480
[40] Erez R, Shabat D. The azaquinone-methide elimination: comparison study of 1,6- and 1,4-eliminations under physiological conditions. Org Biomol Chem 2008; 6: 2669-2672
[41] Xiao D, Zhao L, Xie F, Fan S, Liu L, Li W, et al. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate. Theranostics 2021; 11: 2550-2563
[42] Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D. Light-directed, spatially addressable parallel chemical synthesis. Science 1991; 251: 767-773
[43] Pelliccioli AP, Wirz J. Photoremovable protecting groups: reaction mechanisms and applications. Photochem Photobiol Sci 2002; 1: 441-458
[44] Bryden F, Maruani A, Rodrigues JMM, Cheng MHY, Savoie H, Beeby A, et al. Assembly of high-potency photosensitizer-antibody conjugates through application of dendron multiplier technology. Bioconjug Chem 2018; 29: 176-181
[45] Ito K, Mitsunaga M, Nishimura T, Saruta M, Iwamoto T, Kobayashi H, et al. Near-infrared photochemoimmunotherapy by photoactivatable bifunctional antibody-drug conjugates targeting human epidermal growth factor receptor 2 positive cancer. Bioconjug Chem 2017; 28: 1458-1469
[46] Nani RR, Gorka AP, Nagaya T, Kobayashi H, Schnermann MJ. Near-IR light-mediated cleavage of antibody-drug conjugates using cyanine photocages. Angew Chem Int Ed Engl 2015; 54: 13635-13638
[47] Li J, Xiao D, Xie F, Li W, Zhao L, Sun W, et al. Novel antibody-drug conjugate with UV-controlled cleavage mechanism for cytotoxin release. Bioorg Chem 2021;111:104475
[48] Zang C, Wang H, Li T, Zhang Y, Li J, Shang M, et al. A light-responsive, self-immolative linker for controlled drug delivery via peptide- and protein-drug conjugates. Chem Sci 2019; 10: 8973-8980
[49] Xu Y, Li Z, Malkovskiy A, Sun S, Pang Y. Aggregation control of squaraines and their use as near-infrared fluorescent sensors for protein. J Phys Chem B 2010; 114: 8574-8580
[50] McRae EG, Kasha M. Enhancement of phosphorescence ability upon aggregation of dye molecules. J Chem Phys 1958; 28: 721-722
[51] Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol 2004; 195: 298-308
[52] D'Orazio J, Jarrett S, Amaro-Ortiz A, Scott T. UV radiation and the skin. Int J Mol Sci 2013; 14: 12222-12248
[53] Hapuarachchige S, Huang CT, Donnelly MC, Barinka C, Lupold SE, Pomper MG, et al. Cellular delivery of bioorthogonal pretargeting therapeutics in PSMA-positive prostate cancer. Mol Pharm 2020; 17: 98-108
[54] Lin F, Chen L, Zhang H, Ching Ngai WS, Zeng X, Lin J, et al. Bioorthogonal prodrug-antibody conjugates for on-target and on-demand chemotherapy. CCS Chemistry 2019; 1: 226-236
[55] Wang X, Liu Y, Fan X, Wang J, Ngai WSC, Zhang H, et al. Copper-triggered bioorthogonal cleavage reactions for reversible protein and cell surface modifications. J Am Chem Soc 2019; 141: 17133-17141
[56] Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21: 778-784
[57] Tobaldi E, Dovgan I, Mosser M, Becht JM, Wagner A. Structural investigation of cyclo-dioxo maleimide cross-linkers for acid and serum stability. Org Biomol Chem 2017; 15: 9305-9310
[58] Gregson SJ, Masterson LA, Wei B, Pillow TH, Spencer SD, Kang GD, et al. Pyrrolobenzodiazepine dimer antibody-drug conjugates: synthesis and evaluation of noncleavable drug-linkers. J Med Chem 2017; 60: 9490-9507
[59] Wang Y, Liu L, Fan S, Xiao D, Xie F, Li W, et al. Antibody-drug conjugate using ionized cys-linker-MMAE as the potent payload shows optimal therapeutic safety. Cancers (Basel) 2020; 12: 744
[60] Li X, Patterson JT, Sarkar M, Pedzisa L, Kodadek T, Roush WR, et al. Site-specific dual antibody conjugation via engineered cysteine and selenocysteine residues. Bioconjug Chem 2015; 26: 2243-2248
[61] Lyu Z, Kang L, Buuh ZY, Jiang D, McGuth JC, Du J, et al. A switchable site-specific antibody conjugate. ACS Chem Biol 2018; 13: 958-964
[62] Zhou Q. Site-specific antibody conjugation for ADC and beyond. Biomedicines 2017; 5: 64
[63] Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004; 10: 7063-7070
[64] Lyon RP, Setter JR, Bovee TD, Doronina SO, Hunter JH, Anderson ME, et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat Biotechnol 2014; 32: 1059-1062
[65] Christie RJ, Fleming R, Bezabeh B, Woods R, Mao S, Harper J, et al. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides. J Control Release 2015; 220: 660-670
[66] Fontaine SD, Reid R, Robinson L, Ashley GW, Santi DV. Long-term stabilization of maleimide-thiol conjugates. Bioconjug Chem 2015; 26: 145-152
[67] Christie RJ, Tiberghien AC, Du Q, Bezabeh B, Fleming R, Shannon A, et al. Pyrrolobenzodiazepine antibody-drug conjugates designed for stable thiol conjugation. Antibodies (Basel) 2017; 6: 20
[68] Shaunak S, Godwin A, Choi JW, Balan S, Pedone E, Vijayarangam D, et al. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol 2006; 2: 312-313
[69] Badescu G, Bryant P, Bird M, Henseleit K, Swierkosz J, Parekh V, et al. Bridging disulfides for stable and defined antibody drug conjugates. Bioconjug Chem 2014; 25: 1124-1136
[70] Huang R, Sheng Y, Wei D, Yu J, Chen H, Jiang B. Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates. Eur J Med Chem 2020; 190: 112080
[71] Sun S, Akkapeddi P, Marques MC, Martinez-Saez N, Torres VM, Cordeiro C, et al. One-pot stapling of interchain disulfides of antibodies using an isobutylene motif. Org Biomol Chem 2019; 17: 2005-2012
[72] Huang R, Li Z, Sheng Y, Yu J, Wu Y, Zhan Y, et al. N-Methyl-N-phenylvinylsulfonamides for cysteine-selective conjugation. Org Lett 2018; 20: 6526-6529
[73] Waalboer DC, Muns JA, Sijbrandi NJ, Schasfoort RB, Haselberg R, Somsen GW, et al. Platinum(II) as bifunctional linker in antibody-drug conjugate formation: coupling of a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore to trastuzumab as a model. ChemMedChem 2015; 10: 797-803
[74] Sijbrandi NJ, Merkul E, Muns JA, Waalboer DC, Adamzek K, Bolijn M, et al. A novel platinum(II)-based bifunctional ADC linker benchmarked using 89Zr-desferal and auristatin F-conjugated trastuzumab. Cancer Res 2017; 77: 257-267
[75] Merkul E, Muns JA, Sijbrandi NJ, Houthoff HJ, Nijmeijer B, van Rheenen G, et al. An efficient conjugation approach for coupling drugs to native antibodies via the Pt(II) linker Lx for improved manufacturability of antibody-drug conjugates. Angew Chem Int Ed Engl 2020; 60: 3008-3015
[76] Merkul E, Sijbrandi NJ, Muns JA, Aydin I, Adamzek K, Houthoff HJ, et al. First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs). Expert Opin Drug Deliv 2019; 16: 783-793
[77] Maderna A, Leverett CA. Recent advances in the development of new auristatins: structural modifications and application in antibody drug conjugates. Mol Pharm 2015; 12: 1798-1812
[78] Burke PJ, Hamilton JZ, Pires TA, Setter JR, Hunter JH, Cochran JH, et al. Development of novel quaternary ammonium linkers for antibody-drug conjugates. Mol Cancer Ther 2016; 15: 938-945
[79] Block SS, Stephens RL, Barreto A, Murrill WA. Chemical identification of the Amanita toxin in mushrooms. Science 1955; 121: 505-506
[80] Pando O, Dorner S, Preusentanz R, Denkert A, Porzel A, Richter W, et al. First total synthesis of tubulysin B. Org Lett 2009; 11: 5567-5569
[81] Quintieri L, Geroni C, Fantin M, Battaglia R, Rosato A, Speed W, et al. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res 2005; 11: 1608-1617
[82] Park S, Kim SY, Cho J, Jung D, Seo D, Lee J, et al. Aryl sulfate is a useful motif for conjugating and releasing phenolic molecules: sulfur fluorine exchange click chemistry enables discovery of ortho-hydroxy-protected aryl sulfate linker. Bioconjug Chem 2019; 30: 1957-1968
[83] Han TH, Zhao B. Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos 2014; 42: 1914-1920
[84] Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 2015; 33: 733-735
[85] Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, et al. Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates. Bioconjug Chem 2017; 28: 1371-1381
[86] Abrahams CL, Li X, Embry M, Yu A, Krimm S, Krueger S, et al. Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001. Oncotarget 2018; 9: 37700-37714
[87] Shao S, Tsai MH, Lu J, Yu T, Jin J, Xiao D, et al. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG. Bioorg Med Chem Lett 2018; 28: 1363-1370
[88] Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC, et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem 2011; 54: 3606-3623
[89] Walker JA, Sorkin MR, Ledesma F, Kabaria SR, Barfield RM, Rabuka D, et al. Hydrophilic sequence-defined cross-linkers for antibody-drug conjugates. Bioconjug Chem 2019; 30: 2982-2988
[90] Simmons JK, Burke PJ, Cochran JH, Pittman PG, Lyon RP. Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation. Toxicol Appl Pharmacol 2020; 392: 114932
[91] Viricel W, Fournet G, Beaumel S, Perrial E, Papot S, Dumontet C, et al. Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates. Chem Sci 2019; 10: 4048-4053
[92] Zhang D, Yu SF, Ma Y, Xu K, Dragovich PS, Pillow TH, et al. Chemical structure and concentration of intratumor catabolites determine efficacy of antibody drug conjugates. Drug Metab Dispos 2016; 44: 1517-1523
[93] Zhang D, Yu SF, Khojasteh SC, Ma Y, Pillow TH, Sadowsky JD, et al. Intratumoral payload concentration correlates with the activity of antibody-drug conjugates. Mol Cancer Ther 2018; 17: 677-685
[94] Zhang D, Dragovich PS, Yu SF, Ma Y, Pillow TH, Sadowsky JD, et al. Exposure-efficacy analysis of antibody-drug conjugates delivering an excessive level of payload to tissues. Drug Metab Dispos 2019; 47: 1146-1155
[95] Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res 2015; 21: 5131-5138
[96] Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013; 12: 329-332
[97] Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821
[98] Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28: 2698-2704
Similar articles: